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18-21 months of age. No alterations in specific oncogenes
and inducing an associated inflammatory response leading to and tumour suppressor genes in the HCC arising in this liver cirrhosis and eventually HCC as observed in experimental transgenic model have been observed. However, onset of models (10, 11) . HBV appears to infrequently act by insertional liver tumours is significantly earlier in mice treated with mutagenesis in human HCC as the sites of HBV DNA aflatoxin B 1 (AFB 1 ). In order to examine more generally integration are rarely associated with proto-oncogenes or for genetic rearrangements during the natural history of tumour suppressor genes. Nevertheless, HBV may induce the disease, DNA multilocus fingerprinting was performed chromosomal alterations given the frequent LOH in HCC and using probes recognizing mouse minisatellites. Liver this is suggested by the fact that HBV DNA integration sites tumour samples from HBV transgenic mice either are often associated with deletions, translocations, etc., in untreated or treated with AFB 1 transplacentally were flanking cellular DNA (12); this is of interest given in vitro included in the study. In a total of 28 tumour samples from experiments showing that insertion of HBV DNA can induce HBV transgenic mice receiving no carcinogen treatment, chromosomal instability by promoting genetic recombination using three minisatellite probes, no alterations were (13). detected. The frequency of rearrangements using any one Transgenic mice carrying an integrated subgenomic HBV of the three probes is calculated to be below 0.2%. This DNA fragment coding for the envelope polypeptides of the result demonstrates that genetic instability in minisatellite virus represent a good experimental animal model for the sequences is not a common event associated with HBV study of the mechanisms leading to the development of HCC gene expression and liver injury in this model. In 11 liver (10, 11) . In this model, non-secretable filamentous subviral tumours from mice exposed to AFB 1 transplacentally six hepatitis B surface antigen (HBsAg) particles accumulate had minisatellite alterations (band gains and losses)
within the endoplasmic reticulum of the hepatocytes; this revealed by at least one of the three probes used. The overproduction leads to a progressive liver cell injury characfrequency of rearrangements was between 1.1% and 2%
terized by hyperplasia (as early as 2-3 months of age) and an depending on the minisatellite probe. These data show associated inflammatory response followed sequentially by that genetic alterations can be induced by transplacental chronic hepatocellular regeneration, transcriptional deregulaexposure to AFB 1 and suggest that genetic instability tion, dysplasia, aneuploidy, adenomas and HCC by 18-21 could be important in hepatocarcinogenesis with combined months of age. When these mice are treated with aflatoxin B 1 exposures to AFB 1 and HBV.
(AFB 1 ) there is an earlier onset of liver tumours compared to untreated transgenic mice (14). The similarity of hepatocytes in this transgenic model Introduction to 'ground-glass' hepatocytes characteristic of chronically Chronic hepatitis B virus (HBV*) infection is clearly associated infected human liver suggests that the same mechanisms may with development of primary hepatocellular carcinoma (HCC), be operative in this immunotolerant animal model as in the but the specific molecular mechanisms important in the human healthy chronic carrier state (10) . In order to elucidate development of HCC remain unknown (1) . Since there is a the molecular mechanisms which might contribute to hepatocarcinogenesis in the HBV transgenic mice, several oncogenes 
Materials and methods
Hybridization with the oligonucleotide probe M involved a prehybridization Chemicals step (ϫ5 SSC, 0.5% SDS, 20 min, 50°C); the membrane was then hybridized AFB 1 and DMSO were obtained from Sigma (St Louis, MO, USA).
for 20 min at 50°C in the same buffer containing 10% of casein based blocking buffer and 0.005 nmol probe M. Washing was performed as follows: Animals 2ϫ10 min at 50°C in ϫ4 SSC, 0.1% SDS and 2ϫ5 min at 28°C in ϫ2 SSC, Non-transgenic C57Bl/6 female mice were mated with HBV transgenic males 0.1% SDS. of lineage 50-4 [official designation Tg(Alb-1HBV) Bri 44] containing the DNA fingerprints were evaluated by visual inspection and by densitometry. HBV Bgl II-A fragment downstream of the mouse albumin promoter (11) in Gel resolution permitted examination of DNA fragments between about 2 and the IARC animal facility. Pregnant mice were treated with 4 mg AFB 1 /kg 22 Kb comprising between 20 and 30 bands per blot, depending on restriction body weight (AFB 1 was dissolved in DMSO) or with DMSO by subcutaneous enzyme and probe used. For each animal, the tumour and/or pathologic liver injection on day 17 and 18 of gestation. The full details of this carcinogenicity DNA fingerprints were compared to the DNA fingerprint from the nonexperiment are to be published elsewhere (Wild, Turusov and Chisari, tumourous liver and the brain used as a control tissue. Each DNA sample unpublished data). Fifteen F1 HBV transgenic mice (11 males, four females;
was analysed in at least two independent experiments. five DMSO-treated, 10 AFB 1 -treated) were killed at 98 weeks of age for Rearrangements of minisatellite sequences were defined as band loss or inclusion in the study. In addition, 22 transgenic mice (nine females, 13 band gain with a two-fold or greater change in intensity compared to the males), resulting from mating HBV transgenic female mice with non-transgenic control DNA. A positive result is determined as a reproducible alteration C57Bl6/J males, were killed at age of 49, 79 or 86 weeks to permit further observed at least twice with the same DNA sample processed independently comparison with AFB 1 treated mice. The presence of HBsAg in the serum of from restriction enzyme digest onwards. If differences in DNA quality could F1 mice was determined by ELISA (Abbott, IL, USA).
possibly account for an observed band alteration, the change was not scored.
Liver tumour collection
As band losses and gains could result from the same genetic events in a given tumour these were scored as only one rearrangement when calculating In this transgenic lineage hepatocellular neoplasms occur in virtually all mice rearrangement frequencies. In order to determine the sensitivity of the method by 18-21 months following a progressive liver injury characterized by to detect changes in tumour DNA where normal cells could be present, DNA inflammation, regenerative hyperplasia and dysplasia; the type of tumours from one mouse was mixed with DNA from a second mouse having a different resulting is heterogenous displaying characteristics of hepatocellular adenomas DNA fingerprint. Mixing was performed at various ratios from 10:1 to 1:1 and carcinomas with the latter being more common in older male mice (11) .
and showed that bands from the second mouse were visible once the DNA In our study individual lesions were not always examined histologically from this mouse represented 40% of that in the mixture (data not shown). because of the need to extract sufficient DNA for fingerprinting (see below). Multiple tumours in the same liver were frequently observed, often with one or two large tumours (1-2 cm), whereas in other cases, multiple small nodules
Results
were observed and areas of non-tumourous liver were difficult to identify. Macroscopically-identified liver tumours were isolated from adjacent tissue HBV transgenic mice not receiving AFB 1 treatment were by dissection at necroscopy. Tumours were similar in size in animals treated divided into four groups according to age and nature of the or not with AFB 1 . In some animals, particularly in the oldest mice, it was not possible to isolate individual nodules and, in these cases, nodular regions tissue samples isolated from the liver (see Table I ). Mice from containing one or more individual nodules were analysed together. Tumours, group I, 49 weeks old for the majority, had a macroscopically adjacent macroscopically normal liver (designated non-tumourous liver) and non-tumourous, but enlarged liver. Mice from group II, 79 brain (as a control organ with no HBV associated tissue injury) were frozen weeks old for the majority, had one or more liver tumours that in liquid nitrogen and kept at -80°C until DNA extraction.
could be isolated from an enlarged but non-tumourous liver;
DNA isolation their diameter ranged from 0.5cm for the smallest to 1-2cm DNA was isolated by a phenol-chloroform extraction method and was for the largest ones. Mice from group III, 79 to 86 weeks of determined to be of high molecular weight DNA (Ͼ50 Kb) by analysis on age, had a liver with multiple nodules in which it was difficult 1% agarose minigels.
to define individual lesions or non-tumourous regions of the Probes liver. Mice from group IV, exposed transplacentally to DMSO, Three different oligonucleotide probes were used (Table II) . Probes 33.15 and 33.6 correspond to the human minisatellite core sequences 33.15 and 33.6 were killed at 98 weeks of age and nodules of 0.5-2 cm were isolated. A further 10 HBV transgenic mice (group V) which had been exposed to AFB 1 transplacentally were killed at 98 weeks of age and nodules of 0.5-2cm were also isolated. For each mouse, the brain was also collected as control organ for comparison of DNA fingerprint with pathologic liver. Three different probes were used in order to study different minisatellite families (Table II) . For a single mouse, hybridization with each of the three probes gave a distinct DNA fingerprint (Figure 1 ). In addition, a different fingerprint was observed with a given probe when DNA was digested with the two different restriction enzymes (also see Figure 1 ). While the DNA fingerprints from different mice have similarities they are, nevertheless, distinct for each animal (data not shown). No differences in DNA fingerprints between brain, non-tumourous liver and liver tumours for a given mouse were seen in any of the non-AFB 1 treated mice examined with any of the three probes with either restriction enzyme. Density shifts in some bands were occasionally found in DNA fingerprints, but were never confirmed in repeat experiments and so could not be considered as changes in the pattern. Distinct liver tumours from the same mouse were analysed separately and gave identical DNA fingerprints, the same as the pattern in the corresponding brain and non-tumourous liver (see Given that no band alterations were observed, the corresponding frequency of somatic rearrangements is zero of 529 (23ϫ23) bands for probes 33.6 and 33.15 and of 579 (25ϫ23) bands for probe M giving a frequency of rearrangements below 0.2% for each probe (Table III) . If only those cases are considered in which clearly defined individual tumours were isolated (16 tumours of Group II mice) then the frequency of rearrangements is less than 0.25%. A further five tumour samples were analysed from mice treated transplacentally with DMSO (the vehicle used for the AFB 1 injections) aged 98 weeks (Group IV). Similar to the above 23 tumours, no band alterations were observed compared to DNA extracted from brain. These results clearly indicate that over-expression of the HBV large envelope polypeptide and liver injury associated with this over-expression do not result in generation of genetic rearrangements in minisatellite sequences. Of the 10 mice exposed to AFB 1 transplacentally (Group V) a total of 11 liver tumours were analysed for minisatellite alterations with the three probes. In contrast to the absence of rearrangements with HBV alone six out of 11 tumours (five of 10 mice) from AFB1 treated mice had a rearrangement detected with at least one probe (Table III) . Interestingly, all the rearrangements were seen among the seven male mice and none in the three female mice. Each of the mice with a rearrangement in the liver tumour originated from different litters. In some instances there were mice from the same litter some tumours both band gains and losses were observed but these were only scored as single rearrangements in the calculation of rearrangement frequencies as a band loss and (54.5%) showed a rearrangement with one of the three multigain could result from the same genetic event. In the mice locus probes in mice treated with AFB 1 (Group V). exposed transplacentally to AFB 1 the 11 tumours comprised Probes 33.6 and 33.15 have been extensively used on human four hepatocellular carcinomas (two from one mouse) and tumour DNA and have demonstrated somatic mutations in seven adenomas with three of each revealing a rearrangement various cancer types (29) (30) (31) (32) with between 18 and 86% of with at least one probe.
tumours containing a somatic rearrangement. Both probes cross-hybridize to mouse DNA and detect multiple variable loci (27). Although such probes have not been extensively Discussion used to date in order to detect somatic mutations in the mouse, they appear to detect murine minisatellites that are not highly In this study, DNA fingerprinting was performed on liver tumours from HBV transgenic mice over-expressing the prone to rearrangements (21, 23, 26) . In contrast to 33.6 and 33.15, probe M comprises only the tetranucleotide [GGCA] 7 HBsAg either with or without additional treatment by transplacental exposure to AFB 1 . No genetic alterations were tandem repeat which is found in a 'hot-spot' for recombination within the mouse major histocompatibility complex (MHC) observed in any tumours from HBV transgenic mice without AFB 1 treatment (groups II to IV) while six of 11 tumours locus (28); in addition, two of the most unstable mouse using the probe (GGGCA) 3 and also found no minisatellite rearrangements. The HBV transgenic mice exposed to AFB 1 transplacentally had minisatellite rearrangement rates of 1.1, 1.6 and 2.0% with probes M, 33.15 and 33.6, respectively, rates similar to the chemically-induced tumours referred to above. One explanation for the divergent frequencies of minisatellite rearrangements described above could be a difference in the genetic events occurring during the course of hepatocarcinogenesis depending on the causative agent. The absence of genetic alterations in the minisatellite sequences, highly prone to rearrangements and well represented because of their dispersion throughout the genome, is in line with previous studies on this HBV transgenic model reporting no amplification, rearrangement or over-expression in a considerable number of oncogenes and tumour suppressor genes in animals not receiving carcinogen treatment (11, 15 ). This suggests that over-expression of the HBV genes and the associated liver injury which result, including inflammation, hyperplasia and dysplasia does not result in genetic instability as measured using these multilocus minisatellite probes. It will be important to examine whether liver injury associated with chronic HBV infection in humans is associated with such alterations or not.
The induction of rearrangements in minisatellite sequences with AFB 1 treatment is a novel finding. Young animals are ment of minisatellite rearrangements in 10T1\2 cells by 17β-oestradiol in cells previously transformed with X-rays. The continous presence of the 17β-oestradiol was necessary to minisatellite loci identified to date, Ms6-hm and hm-2, have close homology to the MHC minisatellite : Ms6-hm is based maintain the enhancement of the minisatellite rearrangement frequency. It is possible that the over-expression of the HBV on [GGCAG] tandem repeats, while hm-2 contains [GGCA] tandem repeats (33, 34) . Probe M has been used to detect transgene causing progressive liver injury is acting in a similar way in our model. AFB 1 has been demonstrated to be a minisatellite alterations in murine liver tumours and in transformed cell lines treated with chemical or physical agents. In powerful inducer of mitotic recombination events (38) and this could provide one mechanism by which AFB 1 induces these latter studies, the minisatellite rearrangement frequency (i.e. the number of over-expressiond bands relative to the rearrangements in minisatellite sequences. It will be informative to examine whether minisatellite alterations are induced total number of minisatellite bands examined) was 0.4% in spontaneous CD-1 mouse liver tumours, ranged from 2 to 4%
by AFB 1 treatment of mice under other protocols such as the post-natal exposure used in earlier carcinogenicity studies (14). in chemically-induced CD-1 liver tumours (23,24) and was about 2% in X-ray and UV treated C3H/10T1/2 cell lines (26) .
To our knowledge there are no other examples to date of transplacental treatment inducing minisatellite alterations, but These latter somatic mutation frequencies are at least an order of magnitude higher than the results in our untreated HBV germ line mutations have been induced in mice by ionizing radiation (39) . transgenic mice (frequency Ͻ0.2%). 
